Shestatzky 1988.

Methods	DESIGN Description: random‐assignment, placebo‐controlled, crossover, flexible‐dose, double‐blind, single centre, 2 week placebo washout BLINDING Participants: Unclear Assessors: Yes Administrators: Unclear ALLOCATION CONCEALMENT Method: Claimed, but method not mentioned RANDOMISATION Method: Unclear
Participants	SAMPLE Description: 13 DSM‐III PTSD, mean age: 38.5 years (31‐50), average duration of diagnosis: 5.6 years, 2% (2/10) MDD, baseline severity on IES: phenelzine (34) and placebo (36) SCREENING Primary diagnosis: Not mentioned Comorbidity: Not mentioned
Interventions	Description: phenelzine 30 mg/d ‐ 75 mg/d (avg. max dose: 66 mg/d) versus placebo x 5 weeks
Outcomes	CGI‐I, CGI‐S, CAPS‐2. ITT(LOCF) values provided. Primary outcomes: CAPS‐2, CGI‐I, CGI‐S Secondary outcomes: MADRS Data estimation:
Notes	INDUSTRY SUPPORT Industry funded: No Medication provided by industry: No Any of the authors work for industry: No ADDITIONAL INFORMATION Drop‐out rates: 54% (7/13) on phenelzine and 0% (0/13) on placebo Quality rating score: 14 much of descriptive data for 4 week completers in both phases; supportive psychotherapy provided to patients
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear